Show simple item record

dc.contributor.authorFountzilas, Georgeen
dc.contributor.authorNikolaides, C.en
dc.contributor.authorBafaloukos, Dimitriosen
dc.contributor.authorKalogera-Fountzila, Annaen
dc.contributor.authorKalofonos, H. P.en
dc.contributor.authorSamelis, G.en
dc.contributor.authorAravantinos, Gerasimosen
dc.contributor.authorPavlidis, Nicholasen
dc.creatorFountzilas, Georgeen
dc.creatorNikolaides, C.en
dc.creatorBafaloukos, Dimitriosen
dc.creatorKalogera-Fountzila, Annaen
dc.creatorKalofonos, H. P.en
dc.creatorSamelis, G.en
dc.creatorAravantinos, Gerasimosen
dc.creatorPavlidis, Nicholasen
dc.date.accessioned2018-06-22T09:53:05Z
dc.date.available2018-06-22T09:53:05Z
dc.date.issued2000
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/41654
dc.description.abstractA phase II study was conducted to evaluate the activity and toxicity profile of the combination of docetaxel and gemcitabine in anthracycline- resistant advanced breast cancer (ABC). Thirty-nine eligible patients with a median performance status of 1 (range, 0-2) were enrolled in the study. Treatment consisted of docetaxel 75 mg/m2 in a 1-hr infusion on day 1 preceded by gemcitabine 1000 mg/m2 over 30 min on days 1 and 8. One hundred eighty-one treatment cycles were administered, 113 (62.4%) of them at full dose. Relative dose intensity of gemcitabine and of docetaxel was O.73 and 0.85, respectively. More common grade 3-4 toxicities included neutropenia (49%), anemia (10%), fatigue (10%), nausea/vomiting (8%), and alopecia (77%). Seven patients were hospitalized for febrile neutropenia. Granulocyte colony- stimulating factor (G-CSF) administration was required in 90% of patients. Overall, 14 patients (36%) responded, 3 (7.5%) of them completely. Median duration of response was 10.3 months (range, 4.6-17.5+). Median time to progression was 7 months (range, 0.2-17.5+) and median survival 12.7 months (range, 2-20.5+). In conclusion, the combination of docetaxel and gemcitabine, as used in the present study, has moderate activity in anthracycline-resistant ABC. Future studies should incorporate prophylactic administration of G-CSF to reduce the incidence of febrile neutropenia and maintain dose intensity.en
dc.language.isoengen
dc.sourceCancer investigationen
dc.subjectArticleen
dc.subjectHumanen
dc.subjectHumansen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectBreast canceren
dc.subjectBreast neoplasmsen
dc.subjectFemaleen
dc.subjectMiddle ageden
dc.subjectCancer growthen
dc.subjectCancer survivalen
dc.subjectNeoplasmen
dc.subjectPriority journalen
dc.subjectAlopeciaen
dc.subjectAnemiaen
dc.subjectAntineoplastic combined chemotherapy protocolsen
dc.subjectClinical articleen
dc.subjectClinical trialen
dc.subjectDrug resistanceen
dc.subjectDrug resistanceen
dc.subjectFatigueen
dc.subjectFebrile neutropeniaen
dc.subjectGemcitabineen
dc.subjectNeutropeniaen
dc.subjectOndansetronen
dc.subjectPhase 2 clinical trialen
dc.subjectTaxoidsen
dc.subjectGranulocyte colony stimulating factoren
dc.subjectDocetaxelen
dc.subjectSurvival rateen
dc.subjectGastrointestinal symptomen
dc.subjectAntineoplasticen
dc.subjectDeoxycytidineen
dc.subjectPaclitaxelen
dc.subjectAntibioticsen
dc.subjectAnthracyclineen
dc.subjectPatient complianceen
dc.titleDocetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: A hellenic cooperative oncology group phase II studyen
dc.typeinfo:eu-repo/semantics/article
dc.description.volume18
dc.description.issue6
dc.description.startingpage503
dc.description.endingpage509
dc.author.facultyΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidPavlidis, Nicholas [0000-0002-2195-9961]
dc.contributor.orcidAravantinos, Gerasimos [0000-0002-2106-1713]
dc.contributor.orcidKalogera-Fountzila, Anna [0000-0002-6801-3129]
dc.contributor.orcidKalofonos, H. P. [0000-0002-3286-778X]
dc.gnosis.orcid0000-0002-2195-9961
dc.gnosis.orcid0000-0002-2106-1713|0000-0002-6801-3129
dc.gnosis.orcid0000-0002-3286-778X


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record